News

Phage Display Technology: Market Prospect Analysis And Research Progress

Literature Title: Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells.

On July 31, 2024, in the journal Scientific Reports, Nam Ju Lee et al. published a paper titled A single domain antibody library based on a stability-engineered human VH3 scaffold.

On December 23, 2024, Fan Bu et al. published a paper titled "Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection" in the journal PLOS Pathogens.

Alpha Lifetech Incorporation is revolutionizing the field of biotechnology by offering comprehensive upstream and downstream services tailored for recombinant proteins. With a focus on delivering high-quality protein resources, Alpha Lifetech aims to streamline research and development processes for biopharmaceutical companies. By providing innovative solutions that cater to the industry's specific needs, the company ensures efficient production and purification of proteins. This initiative enhances the capabilities of scientists and researchers and positions Alpha Lifetech as a leader in the biotechnology sector. With a commitment to advancing protein technologies, Alpha Lifetech Incorporation is poised to make significant contributions to scientific breakthroughs and therapeutic developments.

Alpha Lifetech Incorporation has announced a comprehensive review of protein purification, an essential step in the protein production process. The review provides key insights and important points for subsequent experiments and research in the field of protein purification. This review is expected to significantly contribute to the advancement of protein production and development of new therapeutic targets. Alpha Lifetech Incorporation is known for its expertise in biopharmaceutical manufacturing and is committed to providing cutting-edge solutions for protein purification. This review is anticipated to have a major impact on the industry and solidify Alpha Lifetech's position as a leader in biopharmaceutical research and development.

On June 1, 2024, in the journal Nature Communications, scientists from Bo Li's research team published an article titled "Area postrema neurons mediate interleukin-6 function in cancer cachexia". The article found that sustained elevation of interleukin-6 can lead to brain dysfunction and ultimately cancer cachexia.

On July 11, 2024, a team of researchers led by Dr. Judith Sebolt Leopold designed a kinase inhibitor MTX-531 that can block epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-OH kinase (PI3K).